Viacom, Inc. (VIAB) Is At $24.54 Formed Wedge; I-G Investment Management LTD Increased Sarepta Therapeutics (SRPT) Stake By $396,000

November 15, 2017 - By Ellis Scott

Viacom, Inc. (VIAB) formed wedge down with $23.56 target or 4.00% below today’s $24.54 share price. Viacom, Inc. (VIAB) has $10.14B valuation. The stock decreased 0.73% or $0.18 during the last trading session, reaching $24.54. About 10 shares traded. Viacom, Inc. (NASDAQ:VIAB) has declined 8.36% since November 15, 2016 and is downtrending. It has underperformed by 25.06% the S&P500.

I-G Investment Management Ltd increased Sarepta Therapeutics Inc (SRPT) stake by 30% reported in 2017Q2 SEC filing. I-G Investment Management Ltd acquired 12,000 shares as Sarepta Therapeutics Inc (SRPT)’s stock rose 22.49%. The I-G Investment Management Ltd holds 52,000 shares with $1.75 million value, up from 40,000 last quarter. Sarepta Therapeutics Inc now has $3.54 billion valuation. The stock increased 0.55% or $0.3 during the last trading session, reaching $54.79. About shares traded. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 96.82% since November 15, 2016 and is uptrending. It has outperformed by 80.12% the S&P500.

Among 26 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 19 have Buy rating, 1 Sell and 6 Hold. Therefore 73% are positive. Sarepta Therapeutics had 92 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Suntrust Robinson given on Friday, August 7. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Buy” rating given on Monday, September 4 by Cowen & Co. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Buy” rating given on Thursday, October 26 by Needham. The company was maintained on Thursday, September 7 by Credit Suisse. Roth Capital maintained the shares of SRPT in report on Wednesday, August 5 with “Buy” rating. The rating was upgraded by Morgan Stanley to “Overweight” on Monday, October 2. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Outperform” rating given on Monday, September 19 by Robert W. Baird. The stock has “Outperform” rating by Wedbush on Monday, October 10. Leerink Swann maintained Sarepta Therapeutics Inc (NASDAQ:SRPT) on Monday, October 9 with “Buy” rating. The rating was maintained by Jefferies with “Hold” on Tuesday, April 26.

I-G Investment Management Ltd decreased Cigna Corporation (NYSE:CI) stake by 9,000 shares to 40,775 valued at $6.83M in 2017Q2. It also reduced Us Bancorp Del (NYSE:USB) stake by 164,350 shares and now owns 2.39 million shares. Comcast Corp New (NASDAQ:CMCSA) was reduced too.

Investors sentiment increased to 1.52 in 2017 Q2. Its up 0.09, from 1.43 in 2017Q1. It is positive, as 19 investors sold SRPT shares while 41 reduced holdings. 30 funds opened positions while 61 raised stakes. 41.29 million shares or 4.20% more from 39.62 million shares in 2017Q1 were reported. Sphera Funds Ltd accumulated 383,047 shares. Weiss Multi owns 50,000 shares. Gilder Gagnon Howe And Com Limited Liability Corporation owns 0.01% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 14,437 shares. 36,000 were accumulated by State Of Wisconsin Invest Board. 6,861 were accumulated by Lehman Financial Res. Florida-based Raymond James And Associate has invested 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Osterweis Capital Inc invested 0.29% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Great West Life Assurance Can stated it has 4,935 shares. 1.00 million are owned by Citadel Ltd Llc. Pnc Grp Incorporated owns 0% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 18,360 shares. 25,458 are held by Capital Advisers Ltd Limited Liability Company. Two Sigma Limited Liability Corporation invested in 10,566 shares. Emerald Mutual Fund Advisers Tru owns 678,270 shares or 1% of their US portfolio. Nokota Mgmt LP stated it has 0.12% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Macquarie Group Incorporated Ltd reported 33,000 shares.

Among 37 analysts covering Viacom Inc. (NASDAQ:VIAB), 12 have Buy rating, 4 Sell and 21 Hold. Therefore 32% are positive. Viacom Inc. had 111 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Wednesday, November 25 by FBR Capital. Wunderlich maintained the stock with “Buy” rating in Friday, June 17 report. Topeka Capital Markets maintained the stock with “Hold” rating in Wednesday, August 26 report. Drexel Hamilton initiated Viacom, Inc. (NASDAQ:VIAB) on Thursday, January 14 with “Hold” rating. On Thursday, February 9 the stock rating was upgraded by Drexel Hamilton to “Buy”. The rating was maintained by Barclays Capital on Friday, August 4 with “Equal-Weight”. FBR Capital downgraded Viacom, Inc. (NASDAQ:VIAB) rating on Tuesday, November 15. FBR Capital has “Mkt Perform” rating and $44 target. The firm has “Market Perform” rating given on Thursday, October 13 by Wells Fargo. The stock has “Underweight” rating by Atlantic Securities on Friday, August 4. The rating was maintained by Needham on Friday, November 3 with “Hold”.

Analysts await Viacom, Inc. (NASDAQ:VIAB) to report earnings on November, 16 before the open. They expect $0.85 earnings per share, up 23.19% or $0.16 from last year’s $0.69 per share. VIAB’s profit will be $351.22 million for 7.22 P/E if the $0.85 EPS becomes a reality. After $1.17 actual earnings per share reported by Viacom, Inc. for the previous quarter, Wall Street now forecasts -27.35% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com